ALK and neoplasm: In addition, FGFR3-TACC3, CCDC6-RET, BCR-ABL, SYT-SSX1/SSX2, PAX3-FOXO1, TPM3/TPM4-ALK, EBS-FLI1 and other fusion antigens are also immunogenic neoantigens, which provide possible targets for tumor immunotherapy [49–54].